ResMed is a medical device company that makes the machines and masks used to treat sleep apnea and other breathing disorders. It generated $5.15 billion in revenue last year, growing at 10% as it continues to digitize the way patients manage their sleep health at home. After a massive recall by its largest competitor, ResMed has solidified its position as the dominant provider of connected respiratory devices globally.
The investment thesis on ResMed is that its software ecosystem creates high switching costs that protect its 19.6% return on invested capital, even as new weight-loss drugs change the market. While many worry that GLP-1 drugs like Ozempic will eliminate the need for sleep apnea treatment, the actual data suggests these drugs may act as a funnel that brings more undiagnosed patients into the healthcare system.
We think ResMed is a resilient business whose digital health platform is becoming the standard for home-based respiratory care, making it much harder for rivals to win back lost share. The primary risk is a structural decline in the sleep apnea population due to weight loss drugs, but the sheer size of the undiagnosed market provides a long runway for growth.
ResMed’s stock has fallen steadily over the last few years and is currently stuck in a slump. Investors are nervous that new weight-loss drugs will make the company’s sleep machines less necessary for patients. Even though the company remains a dominant leader and is buying other health businesses, the stock price has dropped significantly across recent years.
What does it do?
ResMed is a mature business that earns money by selling cloud-connected medical devices and masks that treat sleep apnea and chronic obstructive pulmonary disease (COPD). The core of the business is a "razor and blade" model: patients buy a CPAP (Continuous Positive Airway Pressure) machine once every few years, but they must buy new masks, filters, and tubing every few months. ResMed also rents out a software-as-a-service platform to home health agencies, which helps them track patient data and manage billing. Revenue flows from hospital systems, medical equipment distributors, and directly from patients through insurance reimbursements.
Where does revenue come from?
The majority of revenue comes from the sale of sleep apnea devices and the replaceable masks used with them. Revenue is split between Devices, which brought in $1.22 billion in the Americas over the first nine months of fiscal 2025, and Masks and other accessories, which accounted for $984 million in the same region. Geographically, the United States, Canada, and Latin America represent the largest market, followed by a combined segment of Europe, Asia, and other international regions.
Revenue Breakdown
Revenue by Geography
Who are its customers?
ResMed serves millions of individual patients with sleep apnea and respiratory conditions, alongside thousands of home medical equipment providers. While the end-users are patients, the buyers are often home medical equipment (HME) providers who distribute the machines and manage the insurance claims. ResMed’s digital ecosystem, AirView, now has over 20 million patients being monitored remotely by their doctors and providers. In its software segment, the company serves thousands of professional care providers in the home health, hospice, and skilled nursing markets.
What gives it staying power?
ResMed has staying power because its devices are integrated into a digital health platform that doctors and patients use every day. Once a patient is set up on the AirView system, the friction of switching to a competitor's machine is high because their historical health data and compliance records live in ResMed’s software.
Where is it headed?
ResMed is focusing its future on becoming a comprehensive digital health company rather than just a hardware manufacturer. Management is investing heavily in artificial intelligence to analyze the billions of nights of sleep data they have collected to improve patient outcomes. If successful, this shift will turn ResMed into a high-margin data and software business that monitors general health through sleep.
Revenue growth has remained consistent at 10% year-over-year as the company captures more of the global sleep market. Revenue reached $1.43 billion in the most recent quarter, showing that demand for both machines and masks is staying high despite new competition.
Cash generation is exceptional, with free cash flow of $1.66 billion in FY2025 nearly matching net income. This high cash conversion reveals a business that does not need to spend heavily on factories to grow, allowing it to return cash to shareholders through buybacks.
The balance sheet is very conservative, carrying a debt-to-equity ratio of just 0.13x. ResMed sits in a position of strength, with enough cash and borrowing power to fund acquisitions in the software space without straining its finances.
ResMed is a financially elite business that translates steady revenue growth into high-margin cash flow with minimal debt.
Profit margins are expanding significantly, with gross margins reaching 61.7% as manufacturing efficiencies take hold. The company is benefiting from a shift toward its higher-margin mask and software segments, which now represent a larger portion of total sales.
The adoption of GLP-1 weight-loss drugs remains the primary long-term threat to ResMed's core sleep apnea market. If a massive portion of the population loses enough weight to eliminate their sleep apnea, the total number of patients needing CPAP machines could eventually shrink.
The global sleep apnea and respiratory care market is valued at approximately $10 billion today and is growing at a mid-single-digit rate. As awareness of sleep health rises, the market is expected to reach $14 billion by 2028. The industry is defined by a rational duopoly where high regulatory hurdles and technical complexity prevent new competitors from entering easily. ResMed stands as the clear leader, holding the largest share of the connected device market and a significant lead in digital health software.
The competitive dynamic is currently lopsided but stable. While barriers to entry for manufacturing medical-grade machines are very high, the competition for masks and accessories is more intense and price-sensitive. Pricing power remains structural because these devices are medical necessities covered by insurance, which prioritizes reliability over the lowest cost.
The primary threat is Philips, which has historically shared the market with ResMed but is currently crippled by a massive product recall. Philips remains the most dangerous threat because it has the existing relationships to reclaim share if it can prove its new devices are safe. Other players like Fisher & Paykel compete well in specific niches, such as masks, but lack ResMed’s full end-to-end software suite.
ResMed is aggressively gaining share while its main rival is sidelined. The company’s revenue growth of 10% during a period of market instability confirms it is absorbing the majority of new patient setups.
ResMed’s primary protection comes from high switching costs embedded in its digital health ecosystem. Once a home health provider integrates ResMed’s AirView software into their clinical workflow, the cost of retraining staff and migrating patient sleep data to a rival is prohibitive. This digital "lock-in" is proven by the company's 20 million+ monitored patients.
The financial data confirms this advantage is durable. An ROIC of 19.6% and gross margins above 60% are exceptional for a hardware-heavy business and prove that ResMed is not competing on price alone. These numbers have remained resilient even as competitors have tried to undercut them.
The moat is widening as ResMed's software becomes the data backbone for the entire sleep apnea industry.
Consistently beat analyst estimates while expanding operating margins to 33.7% in Q2.
Generated $1.66B in FCF and maintained a very low 0.13 debt/equity ratio.
CEO Michael Farrell has led the company through its most successful growth phase since 2013.
Capital Allocation Track Record
ResMed’s management team, led by Michael Farrell, has shown exceptional judgment by transforming a hardware company into a digital health leader. They correctly identified early on that data, not just the machine, would be the key to winning the sleep market. By scaling manufacturing during their largest competitor's recall, they proved they can execute under pressure while maintaining a disciplined balance sheet and high returns on capital.
The primary governance risk is the deep institutional knowledge held by Michael Farrell, who has been CEO for over a decade. While there is a deep bench of experienced executives, the strategic vision for the digital health pivot is closely tied to his leadership. However, the company’s clear financial targets and consistent performance suggest a highly professionalized culture that could withstand a leadership transition.
We expect revenue to grow from $5.7B in FY2026 to $8.4B in FY2031 (~8% CAGR), with EPS growing from $11.11 to $19.31 (~12% CAGR). Revenue growth accelerates as ResMed captures a larger share of the undiagnosed sleep apnea market through its integrated digital health platform. Operating margins expand as the company shifts toward higher-margin software subscriptions and benefits from manufacturing efficiencies. EPS grows faster than revenue because expanding profit margins and consistent share buybacks amplify the bottom line. Operating margin expected to reach ~36% by FY2031.
Digital ecosystem scaling with AI-driven sleep diagnostics. By layering AI on top of its 20 million patient data sets, ResMed can offer predictive health insights that make its software indispensable.
Capturing the massive undiagnosed global sleep apnea population. With over 1 billion people estimated to have sleep apnea globally, ResMed has a decades-long growth runway in emerging markets.
Software segment expansion into broader home health markets. Growing the SaaS segment beyond sleep allows ResMed to own the entire home-based clinical workflow for elderly patients.
GLP-1 weight-loss drugs permanently reduce the sleep apnea market. If widespread drug use significantly reduces the number of patients needing respiratory support, ResMed's core market could shrink.
Philips successfully re-enters the market with a safe product. A credible, safe return from ResMed's largest rival could spark a price war and lead to market share loss.
Regulatory changes reduce insurance reimbursement rates for CPAP therapy. A shift in how Medicare or private insurers pay for sleep treatment would directly hit ResMed's margins and revenue.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach (price-to-earnings applied to next year's earnings). It fits ResMed because the company is a mature, GAAP-profitable leader with highly predictable recurring revenue from its mask and software segments, making earnings the cleanest signal of its long-term value.
Next year's EPS of $12.25 multiplied by a 22x multiple gives a per-share fair value of $270. A 22x multiple sits between high-growth mask peer Fisher & Paykel (33x) and the struggling Philips (14x), a positioning justified by ResMed's superior 24% return-on-equity and its high-margin software ecosystem. We use the deterministic projection for FY2027 EPS of $12.25 as our calculation base.
A 5-year Discounted Cash Flow (DCF) cross-check produces a fair value of $304 — within 13% of our Forward P/E answer of $270, confirming the result. Using a 9.2% discount rate and the deterministic engine's projected free cash flow growth, the DCF valuation is slightly higher because it fully captures the compounding value of the high-margin SaaS recurring revenue. Since both methods yield a value significantly above the current price, we trust the more conservative $270 P/E-based target as our headline figure.
We are assuming mask and consumables revenue continues to grow at a low double-digit rate through FY2028. This is supported by the 12% growth seen in the most recent quarter and the inherent recurring nature of mask replacements for ResMed’s massive installed base of over 20 million cloud-connected devices.
We are assuming the impact from GLP-1 drugs remains a net neutral or slight positive for the patient funnel. Current data suggests that while weight-loss drugs reduce apnea severity, they often move undiagnosed patients into the healthcare system where they are finally screened and prescribed CPAP therapy for their remaining symptoms.
We are assuming that ResMed maintains its dominant market share in the U.S. devices segment despite new competitive launches. The company's "productive paranoia" and continued investment in AI-driven algorithms like SmartCare provide a technical moat that has historically allowed them to out-innovate generic manufacturers and legacy peers.
The biggest risk is a definitive clinical shift where GLP-1 medications become the primary, rather than complementary, treatment for obstructive sleep apnea. This would permanently shrink ResMed's addressable market of new device users, likely compressing the forward multiple from 22x to 12x and knocking roughly $120 off the per-share fair value. Watch for "CPAP Adherence" data in clinical journals for any sign that medicated patients are abandoning their devices entirely.
Bear case ($185): SURMOUNT-OSA clinical trial data shows GLP-1 medications reduce the need for CPAP therapy in more than 40% of patients; or Mask replenishment cycles slow from 6 months to 10 months as patients prioritize spending on weight-loss drug co-pays.
Bull case ($340): SaaS revenue growth accelerates to 15% as MatrixCare and Brightree capture the majority of the post-acute care digital transition; or Device gross margins expand back toward 65% as supply chain costs normalize and the higher-margin Air11 platform reaches 80% of the mix.
Clearthesis wrote this report from 36 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning bullish because ResMed has successfully captured the void left by its competitor's massive equipment recall. By digitizing home sleep care, the company has built a sticky software ecosystem that forces patients to stay with their platform, protecting its high returns even as new medical options emerge.
Skeptics think that popular weight-loss drugs will eventually shrink the total number of people who actually need sleep apnea machines. They argue that as GLP-1 drugs improve patient health and weight, the long-term demand for masks and breathing devices will drop significantly, challenging the company's current growth rate.